GORE TAG Conformable Thoracic Endoprosthesis
W. L. Gore & Associates, Inc. · Decision date Oct 2, 2025
What did the FDA decide?
FDA records P040043/S146 as a supplement to PMA P040043, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 2, 2025.
FDA approval order statement
removal of certain lot acceptance testing for the GORE TAG Thoracic Endoprosthesis and GORE TAG Conformable Thoracic Stent Graft with Active Control System
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 2, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P040043/S146
- Regulatory pathway
- PMA supplement
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- MIH
- Decision code
- OK30
- Decision date
- Oct 2, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT.
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- MIH
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P040043/S143 · Related supplement
GORE TAG Conformable Thoracic Endoprosthesis
P040043/S144 · Related supplement
GORE TAG Conformable Thoracic Stent Graft with ACTIVE CONTROL System (CMDS) 00733132646890; 00733132646906; 007331326
P040043/S146 received
Application receipt date recorded by FDA.
P040043/S145 · Related supplement
Conformable GORE TAG Thoracic Endoprosthesis
P040043/S146 · FDA decision
30-Day Notice
P040043/S147 · Related supplement
GORE TAG Conformable Thoracic Endoprosthesis
P040043/S148 · Related supplement
GORE TAG Conformable Thoracic Stent Graft with ACTIVE CONTROL System
P040043/S149 · Related supplement
GORE TAG Conformable Thoracic Endoprosthesis
Timeline entries are records held by MedtechLedger for P040043. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040043
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
GORE TAG Conformable Thoracic EndoprosthesisP040043/S143 | W. L. Gore & Associates, Inc. | PMA supplement | Jul 16, 2025 | FDA |
| W. L. Gore & Associates, Inc. | PMA supplement | Aug 29, 2025 | FDA | |
Conformable GORE TAG Thoracic EndoprosthesisP040043/S145 | W. L. Gore & Associates, Inc. | PMA supplement | Sep 9, 2025 | FDA |
GORE TAG Conformable Thoracic EndoprosthesisP040043/S147 | W. L. Gore & Associates, Inc. | PMA supplement | Oct 15, 2025 | FDA |
| W. L. Gore & Associates, Inc. | PMA supplement | Mar 9, 2026 | FDA | |
GORE TAG Conformable Thoracic EndoprosthesisP040043/S149 | W. L. Gore & Associates, Inc. | PMA supplement | Mar 9, 2026 | FDA |
Explore the linked device profile
Other records with product code MIH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
RelayPro Thoracic Stent-Graft Delivery SystemP200045/S025 | Bolton Medical, Inc. | PMA supplement | Oct 28, 2026 | FDA |
| Cook, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Cook, Inc. | PMA supplement | Aug 4, 2026 | FDA | |
| Cook Medical Incorporated | PMA supplement | Aug 4, 2026 | FDA | |
| William Cook Europe Aps | PMA supplement | Aug 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
W. L. Gore & Associates, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3450 Kiltie Ln., P.O. Box 2400, Flagstaff, AZ, 86003
Sources and methodology
- Original FDA record: P040043/S146
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






